Rare Disease Day is a good moment to sound a warning that providers of rare medicines may be the next to land in the hot seat, writes Meg Alexander.
Meg Alexander
Advertisement
Meg Alexander is Issues Management Practice Head at inVentiv Health Public Relations.
Articles by Meg Alexander
Following the backlash over the Turing Pharma drug price rise, the healthcare industry can not afford to ignore the signals and must carefully consider what to do next, writes Meg Alexander.
Advertisement
Latest Updated Articles
Navigating Post-Turing: Defining Value In Today’s LandscapePublished: October 2nd 2015 | Updated:
Pushback on Rare Drug Prices: Not So Rare After AllPublished: March 9th 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
2
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
3
In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore
4
FDA Continues to Expand National Priority Voucher Program
5
